-+ 0.00%
-+ 0.00%
-+ 0.00%

Pharvaris Q2 FY26 loss narrows to €47.8 million; R&D expenses rise to €35 million

PUBT·08/12/2026 10:51:17
Listen to the news
Pharvaris Q2 FY26 loss narrows to €47.8 million; R&D expenses rise to €35 million
  • Pharvaris posted a 2Q 2026 loss of EUR 47.8 million; loss per share narrowed to EUR 0.70 from EUR 0.83 a year earlier.
  • R&D spending rose to EUR 35 million from EUR 29.6 million; G&A costs climbed to EUR 15.8 million from EUR 10.8 million.
  • Cash and cash equivalents increased to EUR 318 million as of June 30, 2026, from EUR 292 million at year-end 2025.
  • FDA accepted the deucrictibant IR NDA for on-demand HAE; PDUFA date set for April 23, 2027, while the EMA validated the MAA.
  • CHAPTER-3 Phase 3 topline data for deucrictibant XR expected in 3Q 2026; CEO Berndt Modig said pre-commercial work supports a timely U.S. launch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120650PRIMZONEFULLFEED9808579) on August 12, 2026, and is solely responsible for the information contained therein.